PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,290,846
|
prospect studi investig efficaci safeti scalp cool devic prevent alopecia women undergo neo adjuv chemotherapi breast cancer prevent chemotherapi induc alopecia still repres urgent need everi day clinic practic regard prospect singl center studi includ breast cancer bc patient underw scalp cool devic dignicap neo adjuv chemotherapi aim evalu efficaci safeti devic prevent alopecia one hundr seventi eight patient median age year enrol chemotherapi regimen includ anthracyclin taxan base chemotherapi docetaxel cyclophosphamid anthracyclin taxan base plus carboplatin paclitaxel alon case dose dens schedul use overal success rate paclitaxel alon docetaxel cyclophosphamid anthracyclin taxan sequenti regimen plus carboplatin group anthracyclin taxan base chemotherapi versus taxan base chemotherapi p differ term hair preserv dose dens standard schedul found p earli discontinu scalp cool observ patient although patient experienc advers event patient satisfi devic conclus larg prospect studi confirm help effect scalp cool system prevent alopecia bc patient also undergo sequenti anthracyclin taxan base chemotherapi
|
D001943
|
T191
|
36,290,845
|
mutat landscap patient refer elev hemoglobin level background sinc identif jak vf exon mutat driver mutat polycythemia vera pv molecular test mutat patient erythrocytosi becom routin clinic practic howev incid myeloid mutat common jak vf mutat unselect patient refer elev hemoglobin well studi studi aim character mutat landscap real world popul patient refer erythrocytosi use target next generat sequenc ngs base assay method total patient hemoglobin level gt gl femal gt gl male assess januari may genet variant use oncomin myeloid research assay thermofish scientif waltham usa target key gene diagnost prognost implic hematolog condit full gene gene clinic relev hotspot region panel fusion driver gene gt fusion partner result amp nbsp jak mutat detect patient patient posit jak vf one patient jak exon mutat addit mutat detect jak posit patient tet dnmta asxl srsf bcor tp zrsr diagnosi pv suspect jak negat patient base world health organ diagnost criteria notabl one patient carri mutat srsf tet gene patient carri mutat srsf idh asxl gene three jak negat patient elev hemoglobin test posit bcrabl fusion diagnos chronic myeloid leukemia cml exclud analysi remain jak negat patient diagnos secondari erythrocytosi mutat found case conclus mutat jak mutat frequent identifi patient refer erythrocytosi mutat tet dnmta asxl gene detect jak posit pv patient presenc addit mutat asxl mutat popul implic prognosi incid mutat type identifi patient secondari erythrocytosi like reflect incident age associ clonal hematopoiesi indetermin potenti chip
|
D011086;D011087
|
T033;T047;T191
|
36,290,844
|
preval treatment pattern outcom individu egfr posit metastat non small cell lung cancer canadian real world set comparison exon delet lr exon insert egfr mutat carrier real world evid surround egfr posit nsclc patient canada limit administr databas alberta canada use evalu egfr test mutat preval de novo metastat nsclc well characterist treatment pattern outcom individu exon lr exonin mutat individu underw egfr test egfr posit among egfr posit individu exon mutat lr mutat exonin mutat proport individu initi l system therapi exon lr exonin carrier primari front line system therapi gefitinib afatinib monotherapi individu exon lr mutat versus platinum combin therapi individu exonin mutat exonin cohort wors median overal surviv initi l system therapi month ci estim exon month ci lr cohort month ci find highlight exonin mutat repres rare subset nsclc treatment option limit surviv outcom wors relat individu common type egfr mutat
|
D002289;D008175;D000970
|
T121;T191;T109
|
36,290,843
|
extra nodal lymphoma head neck oral caviti retrospect studi diseas overview lymphoma hodgkin non hodgkin lymphoma one common cancer head neck area extra nodal variant lymphoma rare common non hodgkin lymphoma enhl furthermor difficult diagnos due non specif clinic radiolog featur mimic benign malign clinic manifest studi retrospect studi involv patient affect head neck enhl period patient underw diagnost therapeut procedur accord guidelin year follow base locat swell time diagnosi patient divid two group oral non oral enhl statist analysi perform use kaplan meier analysi log rank test addit fisher exact test appli two group evalu compar varianc accept signific level set p lt conclus enhl oral local much aggress enhl non oral local death rate versus non oral one fact two group statist signific differ mortal p valu respect
|
D006258;D008228;D008224
|
T191
|
36,290,842
|
extern valid grade prognost assess patient brain metastas small cell lung cancer recent grade prognost assess gpa small cell lung cancer sclc patient brain metastas develop includ age perform status number brain metastas presenc extracrani metastas aim present studi valid four tier prognost score european cohort patient
|
D055752;D001932;D008175
|
T191
|
36,290,841
|
lesson learn implement person centr digit health platform cancer care sar cov covid pandem acceler develop use digit health platform support individu health relat challeng even frequent field cancer care global burden diseas continu increas everi year howev optim implement platform clinic set requir care plan collabor implement project launch centr intgr universitair de sant et de servic sociaux ciusss du centr ouest de ile de montreal belong beat cancer togeth person centr cancer navig support digit health platform goal project implement content featur specif ciusss made avail exclus individu cancer caregiv treat institut guid structur model interprofession collabor report implement process involv divers stakehold includ clinician hospit administr research local communitypati repres lesson learn includ earlier identif share goal clear expect consist relianc virtual mean communic among involv patientcaregiv involv step ensur inform share decis make
|
D000086382;D009369
|
T047;T191;T067
|
36,290,840
|
surgic manag transpos ovarian recurr cervic cancer systemat review experi earli stage cervic cancer ovarian metastasi relat rare ovarian transposit often perform surgeri although rare diagnosi surgic approach recurr transpos ovari challeng studi focus diagnosi surgic manag transpos ovarian recurr cervic cancer patient year old premenopaus woman underw radic hysterectomi bilater salpingectomi pelvic lymphadenectomi follow postop concurr chemoradiotherapi stage ib cervic cancer initi surgeri ovari transpos paracol gutter postop complic observ ovarian recurr diagnos use positron emiss tomographi comput tomographi laparoscop bilater oophorectomi perform systemat review identifi nine women transpos ovarian recurr metastas cervic cancer studi discuss optim surveil transpos ovari n four women die diseas within year second surgeri prognosi transpos ovarian cervic cancer seem poor nevertheless three women underw laparoscop oophorectomi none experienc recurr second surgeri studi examin surgic manag transpos ovarian recurr optim surgic approach transpos ovarian recurr cervic cancer requir investig
|
D002583;D010051
|
T191
|
36,290,839
|
gastrointestin stromal tumor year experi cancer center ottawa hospit toh background manag gastrointestin stromal tumor gist signific evolv last two decad introduct tyrosin kinas inhibitor tki aim report year experi gist manag region cancer center canada method retrospect analyz record consecut patient diagnos gist describ clinic patholog data manag outcom includ surviv result common gist site stomach follow small bowel diagnosi patient local diseas stage iii accord modifi nation institut health consensus criteria nih gist around intermedi high risk diseas patient underw curat surgic resect forti nine patient receiv adjuv imatinib forti three patient advanc diseas receiv least one line tki median follow month year recurr free surviv rfs rate low low risk respect intermedi high risk respect year overal surviv os rate low low risk intermedi high risk advanc respect use kaplan meier method statist signific differ rfs os nih risk group p lt univari analysi ecog site mitosi secondari malign size predictor os high mitosi larg size gt cm associ wors rfs conclus curat surgic resect remain gold standard manag gist result compar report literatur research need explor histolog role risk stratif initi adjuv tki
|
D046152;D000970
|
T121;T191;T109
|
36,290,838
|
palliat care outcom scale assess cancer patient elig palliat care perspect relationship patient report outcom object assess background import patient report outcom pro ie priorit patient voic increas cancer treatment well palliat support set integr palliat care outcom scale ipo hybrid evalu consist patient evalu pro peer evalu medic profession develop successor version support team assess schedul stas util worldwid japanes version ipo ipo j develop releas purpos studi explor applic ipo j clinic practic futur method conduct follow two studi termin ill cancer patient evalu ipo j perform medic profession peer evalu replac stas j evalu ii qualiti palliat care improv combin ipo j patient evalu peer evalu result overal intervent rate urgent intervent rate stas j ipo j vs p vs p respect patient select intervent requir medic profession select intervent requir case medic team perform appropri intervent assess result patient intervent free week intervent conclus ipo j peer evalu use stas j evalu hybrid type evalu combin patient evalu pro peer evalu may help us understand patient need improv qualiti palliat care
|
D010166;D009369
|
T061;T191
|
36,290,837
|
canadian perspect treatment waldenstrm macroglobulinemia waldenstrm macroglobulinemia wm slowli progress b cell non hodgkin lymphoma character monoclon igm gammopathi blood infiltr bone marrow clonal lymphoplasmacyt cell incur diseas goal therapi wm reliev symptom slow diseas progress prevent organ damag maintain qualiti life howev given rariti wm clinic trial compar treatment wm limit definit standard care select first line wm therapi thus base patient factor diseas characterist drug access bendamustin rituximab bruton tyrosin kinas btk inhibitor therapi consid prefer treatment treatment proteasom inhibitor purin analogu base therapi altern chemoimmunotherapi autolog stem cell transplant general reserv relaps set may use rare circumst earlier line therapi paper summar efficaci safeti wm therapi discuss consider treatment canadian perspect
|
D008258;D018380
|
T061;T191
|
36,290,836
|
psychoneurolog symptom biomark stress inflamm newli diagnos head neck cancer patient network analysi psychoneurolog symptom common report newli diagnos head neck cancer hnc patient yet limit research associ symptom biomark stress inflamm articl pre treatment data multi center cohort hnc patient analyz use network analysi examin connect symptom poor sleep qualiti anxieti depress fatigu oral pain biomark stress diurnal cortisol slope inflamm marker c reactiv protein crp interleukin il il tumor necrosi factor alpha tnf covari age bodi mass index bmi three central indic calcul degre number connect close proxim variabl variabl between base number time variabl locat shortest path pair variabl sampl patient poor sleep qualiti fatigu highest degre index fatigu crp highest close index il highest between index model yield two cluster symptom cortisol slope crp cluster il il tnf age bmi cluster cluster connect promin via il find provid evid poor sleep qualiti fatigu crp il play import role interconnect psychoneurolog symptom biomark stress inflamm newli diagnos hnc patient
|
D007319;D006258
|
T184;T047;T191;T048
|
36,290,835
|
treatment non small cell lung cancer multipl option precis medicin recent year advanc molecular diagnost transform manag advanc non small cell lung cancer nsclc allow increas person approach
|
D002289;D008175
|
T191
|
36,290,834
|
botulinum neurotoxin treatment pharyngocutan fistula salvag surgeri head neck cancer patient preliminari result object analyz effect intraparotid inject botulinum neurotoxin bont salivari product cours pharyngocutan fistula pcf post radiat therapi salvag surgeri method total patient undergon total laryngectomi pharyngolaryngectomi treat bont parotid gland within three day pcf onset salivari flow evalu use subject rate scale percentag normal function saliva normal saliva flow inject everi day week week three month pcfs monitor daili result spontan closur pcf occur case day rang treatment patient need revis surgeri salivari flow signific decreas patient seven day inject p lt patient undergon either conserv surgic treatment differ salivari flow inject wherea mean percentag salivari flow calcul time point inject differ p lt conclus bont contribut closur fistula case subject percept salivari flow predict closur pcf mean time closur may contribut establish time pcf surgic treatment
|
D019274;D007822;D017577;D010608;D006258
|
T129;T121;T116;T190;T109;T131;T191;T047
|
36,290,833
|
preoper omega omega fatti acid ratio could predict postop outcom patient surgic resect non small cell lung cancer introduct aim studi determin whether preoper nutrit status inflammatori status specif polyunsatur acid omega ratio would affect postop outcom complic patient lung cancer undergo lung resect method prospect observ studi includ patient earli stage non small cell lung cancer candid radic surgeri complet nutrit assess perform primari studi variabl postop complic mortal first day descript bivari logist regress analys carri result total men women underw surgeri median age year mean omega ratio complic occur studi sampl n common persist air leak n perform bivari analysi variabl remain signific omega ratio observ prognost valu persist air leak p independ age sex comorbid preoper respiratori function approach type surgeri remain nutrit inflammatori marker statist signific associ p gt postop complic howev signific maintain multivari analysi small margin p ci conclus omega ratio may prognost factor air leak independ patient clinic patholog characterist
|
D002289;D008175;D015525
|
T121;T123;T191;T109
|
36,290,832
|
emerg system therapi advanc unresect biliari tract cancer review canadian perspect biliari tract cancer btc group rare aggress malign dismal prognosi current signific lack effect treatment option btc gemcitabin cisplatin remain first line standard care treatment decad wave investig therapi includ new chemotherapi combin immunotherapi biomark driven target therapi demonstr promis result btc hope mani therapi incorpor canadian treatment landscap near futur review discuss emerg therapi investig btc provid perspect may fit canadian practic focus barrier treatment access
|
D001661;D001650
|
T191
|
36,290,831
|
quantit analysi sar cov antibodi level cancer patient post three dose immun prior breakthrough covid infect background covid vaccin effect care evalu explicit defin knowledg first report quantit evalu humor respons post dose sar cov immun prior breakthrough covid infect canadian cancer patient method prospect cohort studi enrol cancer particip post covid vaccin kingston ontario canada igg antibodi sar cov spike receptor bind domain quantifi immunoassay post three dose immun covid rapid antigen test polymeras chain reaction pcr breakthrough infect identifi result follow sar cov vaccin includ bntb azd mrna mean serum anti spike protein antibodi level bauml bind antibodi unit sd bauml bauml post first second third dose vaccin observ differ signific p averag antibodi level bauml post third dose time seroconvers level bauml indic vaccin approv effect produc robust antibodi respons breakthrough case confirm pcr prior infect averag antibodi concentr bauml highest concentr bauml compar averag antibodi concentr bauml time seroconvers concentr singl dose doubl vaccin tripl vaccin cancer patient higher sar cov antibodi level patient split hematolog solid cancer hematolog cancer group demonstr lower serolog respons solid cancer group first second dose first dose averag concentr vs bauml respect p lt second dose averag concentr vs bauml respect p lt differ third dose level vs bauml p conclus vaccin effect produc robust antibodi respons one dose given dose higher serolog respons like due high contagi natur sar cov variant signific number particip sar cov antibodi respons lower averag antibodi concentr prior known breakthrough infect addit vaccin like requir ensur immun infect sar cov
|
D000086382;D009369
|
T047;T191;T067
|
36,290,830
|
hepat abscess follow yttrium radioembol patient surgic bilioenter anastomosi compromis sphincter oddi tertiari cancer center experi purpos describ experi develop hepatobiliari infect patient prior surgic percutan endoscop biliari intervent receiv transarteri radioembol tare yttrium primari metastat hepatobiliari lesion method record patient histori prior biliari intervent liver malign subsequ treat tare particip medic center novemb septemb review primari endpoint develop hepat abscess cholang patient radioembol result total patient compris men women median age year rang underw tare procedur patient develop hepatobiliari infect singl patient develop hepatobiliari abscess conclus studi show low incid rate hepat abscess follow tare patient prior biliari intervent
|
D009803;D008100;D009369
|
T023;T191;T047
|
36,290,829
|
dose volum constraint organ risk radiotherapi corsair one multicent multidisciplinari practic summari safe use radiotherapi rt requir complianc dosevolum constraint dvcs organ risk oar howev avail recommend sometim conflict scatter across number differ document therefor aim work provid singl document practic indic dvcs oar extern beam rt avail literatur
|
D050397;D016634
|
T061
|
36,290,828
|
assess health relat qualiti life distress asian communiti base cancer rehabilit program cancer survivor reduc health relat qualiti life hrqol high level distress activ treatment due physic psycholog social problem understand preval associ hrqol distress patient popul communiti import design rehabilit program cross section observ studi conduct communiti base cancer rehabilit center aim investig preval associ hrqol distress cancer patient patient recruit found low level hrqol high level distress patient mean fact g total score mean distress thermomet score multivari regress model signific factor low hrqol metastat diseas p malay ethnic p lt regress analys also found signific distress associ famili health issu p depress p worri p breath p get around p indigest p high preval impair hrqol distress report cancer survivor even communiti rehabilit set physic psychosoci well cancer survivor monitor manag part communiti base cancer rehabilit
|
D000073116;D009369
|
T201;T191;T101
|
36,290,827
|
novel ferroptosi relat signatur predict prognosi immun profil drug sensit hepatocellular carcinoma patient hepatocellular carcinoma hcc malign diseas increas incid high mortal rate ferroptosi novel type cell death report close associ progress hcc aim studi construct novel ferroptosi relat signatur nfrgs predict prognosi immun featur drug sensit hcc patient data obtain tcga icgc gse ccle imvigor dataset least absolut shrinkag select oper lasso use construct nfrgs addit analys involv prognos molecular function stem indic somat mutat respons immunolog therapi efficaci transcathet arteri chemoembol tace therapi drug sensit perform use divers packag r low high risk group nfrgs includ seven ferroptosi relat gene result show nfrgs independ risk factor prognos hcc patient hcc patient high risk group present wors prognosi compar result studi nfrgs superior promis signatur predict prognos patient hcc addit enrich pathway differenti express gene deg subgroup relat immun featur molecular function genet mutat mrnasi vari high low risk group moreov observ signific immunosuppress state high risk group patient high risk group might benefit immunotherapi wherea patient low risk group may suscept tace therapi final five sensit drug four sensit drug screen patient high low risk group respect nfrgs may serv novel biomark prognosi aid person therapeut strategi patient hcc
|
D006528;D008113;D000079403;D016461
|
T061;T191;T043
|
36,290,826
|
lesson cost effect analysi smoke cessat program cancer patient smoke among patient diagnos cancer pose import health financi challeng includ reduc effect expens cancer therapi studi explor valu smoke cessat program scps patient alreadi diagnos cancer also identifi condit spcs may wise invest
|
D016540;D009369
|
T055;T191
|
36,290,825
|
lung metastatectomi laser assist surgeri make differ resect lung metastas curat intent select patient associ prolong surviv laser assist resect lung metastas result complet resect high number lung metastas preserv lung parenchyma howev data concern laser lung resect scarc contradictori aim studi conduct systemat review evalu util laser assist pulmonari metastasectomi
|
D059146;D053685;D008175
|
T061;T074;T191
|
36,290,824
|
contralater neck irradi omit select later oral cancer local advanc stage background investig contralater neck failur crf rate outcom among patient well later local advanc oral caviti squamous cell carcinoma oscc withwithout ipsilater bilater neck adjuv irradi method patient later oscc diagnos retrospect enrol patient undergon curat surgeri patholog proven pt pn b without distant metastasi includ cross midlin neck level involv posit extra nodal extens ene exclud primari endpoint cumul incid year crf first site failur secondari endpoint includ cancer specif surviv css local region recurr free surviv lrrfs distant metastasi free surviv dmfs contralater region recurr free surviv crrfs result total patient analyz median follow time year rang patholog stage respect patholog negat posit lymph node respect cumul year crf rate ci signific differ year css lrrfs dmfs crrfs observ among undergo unilater bilater neck irradi five patient contralater neck recurr simultan local recurr isol contralater neck recurr identifi conclus crf rate accept low patient well later advanc oscc initi uninvolv contralater neck omit contralater neck irradi activ surveil could consid without compromis cure rate local advanc oscc patient
|
D009062;D002294;D006258
|
T191
|
36,290,823
|
impact nutrit counsel head neck cancer suffer undergo antineoplast therapi random control pilot studi head neck cancer hnc suffer usual encount arduous nutrit problem receiv antineoplast therapi consequ presenc anxieti depress common observ popul studi aim explor physic psycholog influenc nutrit counsel patient hnc patient receiv concurr chemo radiotherapi random assign nutrit counsel group n control group n accord treatment pattern nutrit counsel group regist dietitian provid face face counsel antineoplast treatment cours least everi two week nutrient intak amount relev nutrit index qualiti life degre anxieti depress compar two group observ decreas calori protein intak amount group decreas control group even wors weight loss obvious control group had score intervent group signific lower control group p lt karnofski perform status kps score intervent group signific higher control group p lt level serum total protein serum albumin transferrin thick tricep skin fold decreas less intervent group p lt find suggest nutrit counsel essenti mainten calori protein intak hnc suffer contribut improv physic psycholog state impact observ pilot studi warrant explor larger prospect trial
|
D006258;D000970
|
T121;T191;T109
|
36,290,822
|
decreas foxo express correl poor prognosi myelodysplast syndrom myelodysplast syndrom one main hematolog malign threaten health elder howev biomark predict progress prognosi mds still controversi puzzl foxo gene play import role varieti intracellular function includ tumor suppress cellular immun regul howev research report correl foxo clinic featur mds includ immun environ studi observ foxo express associ neutrophil count blast chromosom differ mds score system foxo express close relat mds cell immun polar increas express foxo signific relat amplif immun cell polar ratio addit foxo express associ progress free surviv overal surviv mds patient moreov multivari model foxo low express independ predictor poor surviv mds summari foxo may play candid tumor suppressor mds foxo use independ prognost predictor mds may provid candid target therapi futur
|
D009190
|
T046;T191
|
36,290,821
|
overexpress scyl associ progress breast cancer scyl pseudokinas play role cell divis gene transcript nuclearcytoplasm shuttl trna protein glycosyl golgi morpholog howev role scyl human breast cancer progress remain larg unknown studi determin express scyl breast cancer search cancer genom atlas tcga tumor immunoassay resourc timer databas meanwhil collect breast tumor tissu sampl case detect express scyl tumor use tissu microarray assay tma associ scyl prognosi breast cancer determin base prognoscan databas result shown scyl overexpress breast cancer express scyl associ poor clinic outcom breast cancer patient furthermor knockdown scyl shrnas signific inhibit prolifer migrat breast cancer cell taken togeth data suggest scyl biomark poor prognosi breast cancer promot role breast cancer progress potenti target breast cancer therapi
|
D001943
|
T191
|
36,290,820
|
primari vitreoretin lymphoma current diagnost laboratori test new emerg molecular tool primari vitreoretin lymphoma pvrl rare aggress malign primarili involv retina andor vitreous major diagnost challeng clinician common misdiagnos chronic uveiti well pathologist biolog technic reason delay diagnosi treatment respons visual impair life threaten consequ usual relat central nervous system involv identif lymphoma cell vitreous fluid obtain vitrectomi requir diagnosi note scarciti neoplast cell small volum vitreous sampl fragil lymphoma cell degen chang caus previous steroid use presum uveiti make diagnosi base cytolog plus immunophenotyp difficult interleukin level immunoglobulin heavi chain cell receptor gene rearrang myd mutat appli combin cytolog support diagnosi aim describ current laboratori technolog pvrl diagnosi focus main issu method addit new emerg diagnost strategi next generat sequenc analysi discuss genet profil pvrl remain larg unexplor better knowledg genet alter critic precis medicin intervent target base treatment lymphoma standardis treatment protocol current exist
|
D019572;D008223;D014605
|
T047;T191
|
36,290,819
|
noninvas determin idh status glioma use mri mri base radiom impact diagnosi prognosi glioma common primari malign brain tumor adult fifth edit classif tumor central nervous system publish provid molecular practic approach cns tumor taxonomi current molecular featur essenti differenti histolog subtyp glioma recent studi emphas import isocitr dehydrogenas idh mutat stratifi biolog distinct subgroup glioma idh play signific role gliomagenesi associ idh status prognosi clear recent much progress convent mr imag cmri advanc mr imag amri radiom wide use studi glioma advanc result improv correl mr sign idh mutat status complement predict idh phenotyp although imag current substitut genet test imag find shown promis sign diagnos glioma subtyp evalu efficaci prognosi individu molecular target therapi review focus correl mri mri base radiom idh gene phenotyp predict discuss valu applic techniqu diagnosi evalu prognosi glioma
|
D001932;D005910
|
T191
|
36,290,818
|
role immunotherapi pancreat cancer pancreat adenocarcinoma remain one lethal cancer global signific need improv therapeut option recent breakthrough immunotherapi checkpoint inhibitor dramat chang treatment paradigm malign base consider surviv benefit pancreat cancer chemotherapi modest benefit still cornerston advanc pancreat cancer treatment pancreat cancer inher immun cold tumor larg refractori immunotherapi clinic trial understand overcom current failur immunotherapi elucid resist mechan develop novel therapeut approach essenti har potenti durabl benefit immun modul therapi pancreat cancer patient
|
D010190;D000230
|
T191
|
36,290,817
|
crosstalk immun checkpoint modul metabol reprogram cellular plastic tripl negat breast cancer breast cancer one major caus mortal women worldwid account breast cancer diagnos tripl negat breast cancer tnbc subtyp present aggress clinic cours heighten metastat potenti poorest short term prognosi tnbc respond hormon therapi partial respond radio chemotherapi limit target therapi option thus underlin critic need better therapeut treatment although immunotherapi base immun checkpoint inhibit emerg promis treatment option tnbc patient activ cellular plastic program metabol reprogram mr epitheli mesenchym transit emt caus immunotherapi fail report review role mr emt immun checkpoint dysregul tnbcs specif shed light develop novel combin treatment modal challeng diseas highlight clinic relev crosstalk mr emt immun checkpoint tnbcs
|
D064726
|
T191
|
36,290,816
|
prognost nomogram base log odd posit lymph node predict overal surviv non metastat bladder cancer patient radic cystectomi purpos purpos studi evalu prognost capac patholog n status pn lymph node ratio lnr log odd posit lymph node lodd build prognost nomogram predict overal surviv os bladder cancer patient treat radic cystectomi method clinic patholog characterist patient bladder cancer identifi surveil epidemiolog end result seer databas predict capac assess univari multivari cox regress analys area receiv oper characterist curv auc c index calibr curv decis curv analysi dca risk group util evalu predict accuraci discrimin abil nomogram result lodd independ risk factor bladder cancer p lt demonstr highest valu c index auc valu auc train cohort predict year os respect calibr curv dca curv suggest excel clinic applic valu nomogram conclus lodd better predict indic bladder cancer patient compar pn lnr lodd incorpor nomogram excel accuraci promis clinic applic valu non metastat bladder cancer radic cystectomi
|
D049451;D001749
|
T081;T170;T191
|
36,290,815
|
challeng patient select prostat cancer focal therapi retrospect observ multicentr studi increas diagnos silent prostat cancer pca led overtreat consequ function side effect focal therapi ft appli energi prostat index lesion treat clinic signific pca focus analys potenti predict factor ft failur collect data patient underw robot assist radic prostatectomi rarp two high volum hospit januari januari inclus criteria one mri detect lesion gleason score gs cta psa ngml gs random biopsi posit foci potenti oncolog safeti ft defin respect clinicopatholog inclus criteria histolog specimen extracapsular extens biochem local metastat recurr within month predict ft failur perform uni multivari logist regress sixti seven patient enrol mri index lesion median size mm target lesion isup grade patient isup grade potenti ft failur occur patient psa valu result predict paramet p lt main issu ft patient select main multifoc cspca foci nevertheless ft could repres therapeut altern high select low risk pca patient
|
D017430;D011471
|
T129;T191;T126;T116
|
36,290,814
|
issu prospect current endoscop treatment strategi superfici non ampullari duoden epitheli tumor increas number duoden tumor diagnos year lead increas confus regard choic treatment option small larg tumor histolog type vari adenoma carcinoma treatment method may need select accord lesion characterist anatom characterist complic like occur duodenum gastrointestin organ sever report describ outcom convent endoscop mucos resect endoscop submucos dissect cold snare polypectomi underwat endoscop mucos resect endoscop full thick resect laparoscop endoscop cooper surgeri duoden tumor howev even guidelin set various countri treatment method list clear treatment strategi provid although report suffici high level evid consid current avail treatment option essenti report review previous report treatment strategi discuss current issu prospect propos best possibl treatment strategi
|
D004379;D003111;D000236
|
T191;T190
|
36,290,813
|
diagnosi treatment prognosi primari pulmonari nut carcinoma literatur review nut carcinoma rare high lethal cancer character rearrang nuclear protein testi nut gene chromosom q primarili occur midlin organ primari pulmonari nut carcinoma nc lack characterist clinic manifest lead high rate misdiagnos nonstandard treatment date fewer one hundr case report worldwid comprehens literatur search involv total articl patient conduct paper review analyz associ clinic patholog characterist efficaci various treatment option prognosi pulmonari nc main occur middl young age men median age smoke histori would present symptom cough dyspnea chest pain hemoptysi initi imag frequent reveal larg irregular lesion lower lobe left right lung lymph node metastasi also preval focal squamous differenti abrupt keratin often occur undifferenti poor differenti tumor cell abund necrosi numer neutrophil infiltr mean overal surviv os patient malign diseas month median os month accord result diseas sensit radiotherapi chemoradiotherapi either concurr chemoradiotherapi sequenti chemoradiotherapi effici therapeut regimen prolong os patient pulmonari nc
|
D002277;D008175
|
T191
|
36,290,812
|
real world treatment pattern clinic outcom canadian patient aml unfit first line intens chemotherapi acut myeloid leukemia aml hematolog malign predomin affect elder prognosi declin age toler intens chemotherapi histor establish treatment option hypomethyl agent hmas low dose cytarabin ldac best support care bsc standard care evolv unfit intens chemotherapi need understand establish treatment pathway clinic outcom healthcar resourc util canada current studi retrospect chart review aml patient elig intens chemotherapi initi first line treatment januari decemb data collect canadian patient treat six hematolog center receiv system therapi receiv bsc first line treatment median overal surviv month vari month bsc month hmas patient least one outpati visit patient receiv system therapi receiv bsc least one admiss hospit first line therapi total patient receiv first line system therapi receiv first line bsc least one red blood cell platelet transfus find highlight unmet need novel therapi patient inelig intens chemotherapi
|
D015470
|
T191
|
36,290,811
|
therapeut manag chronic lymphocyt leukemia present recurr massiv ascit chronic lymphocyt leukemia cll lymphoprolif malign categor product accumul cd monoclon b cell lymphocyt common spleen bone marrow peripher blood morpholog matur lymphocyt abnorm immun function ascit although common solid organ malign ovarian breast gastrointestin rare clinic manifest hematolog malign case present herein describ elder male patient cll present transud ascit year complet chemotherapi microscop analysi flow cytometri patient ascit fluid consist cll treat six cycl obinutuzumab immunotherapi addit acalabrutinib result near resolut malign ascit case report cll manifest transud exud ascit elder patient previous case report develop ascit month initi treatment cll chemotherapi uniqu featur patient present malign ascit near year initi cll treatment chemotherapi intent case report bring awar ascit possibl initi present symptom cll patient isol abdomin distent without common clinic featur leukemia ie splenomegali lymphadenopathi b symptom therapeut manag thereaft malign ascit may associ relaps transform leukemia thus prompt diagnosi treatment delay
|
D015451
|
T191
|
36,290,810
|
rare insidi toxic new combin therapi metastat renal cell cancer lesson learn real practic advent immun checkpoint inhibitor combin multitarget tyrosin kinas inhibitor becom standard first line treatment metastat renal cell cancer along surviv improv new toxic emerg advers event still complex manag rare could insidi even fatal medic oncologist dispos guidelin manag toxic immun checkpoint inhibitor combin therefor still difficult proper attribut manag addit overlap advers event report two clinic case regard rare treatment relat endocrin toxic hypophys thyroid particular focus manag purpos immun checkpoint relat toxic guidelin repres start point howev implement addit measur need consid increas complex current clinic scenario goal correct recogn advers event address side effect discontinu effect treatment therefor aim discuss point proper manag toxic individu potenti area improv
|
D002292;D007680
|
T191
|
36,290,809
|
classif pediatr ganglioglioma base histolog infiltr ganglioglioma well circumscrib low grade glioneuron tumor broad morpholog spectrum diffus glioneuron tumor use describ case infiltr growth molecular studi case consist ganglioglioma work aim clarifi growth pattern ganglioglioma avail slide clinic molecular inform patient sampl diagnosi ganglioglioma open pediatr brain tumor atlas children brain tumor network databas review confirm integr diagnosi evalu growth pattern case ten sampl nine patient exclud slide avail integr diagnos chang seven case nine sampl ten case ten sampl diagnos low grade glialglioneuron tumor diagnosi ganglioglioma confirm seventeen sampl sixteen patient nine femal seven male age rang eight month year mean year infiltr defin presenc neoplast cell among nonneoplast parenchyma growth pattern predomin circumscrib six case predomin infiltr five case combin growth pattern five case work confirm presenc infiltrativediffus variant ganglioglioma signific pattern differenti diagnosi case main infiltr glioma usual idh wild type popul may introduc high grade glioma differenti awar infiltr ganglioglioma variant help scenario
|
D018303;D005910;D001932
|
T191
|
36,290,808
|
case report longitudin collect tumour biopsi gene express base tumour microenviron analysi pancreat cancer patient treat endoscop ultrasound guid radiofrequ ablat patient pancreat ductal adenocarcinoma pdac metastat present dismal prognosi warrant improv system therapi option longitudin sampl assess treatment respons pose challeng valid novel therapi case studi evalu feasibl collect endoscop ultrasound eus guid longitudin fine needl aspir biopsi fnab two pdac patient conduct gene express studi associ tumour microenviron chang associ radiofrequ ablat rfa
|
D010190;D021441;D000078703
|
T061;T191
|
36,290,807
|
strn alk fusion lung adenocarcinoma brain metastasi respond well ensartinib case report strn alk fusion rare alk rearrang identifi non small cell lung cancer nsclc patient report case lung adenocarcinoma brain metastasi harbor strn alk fusion respond well ensartinib case report could provid inform therapeut strategi select nsclc patient harbor strn alk fusion
|
D002289;D008175;D000077192;D001932
|
T191
|
36,290,806
|
virtual person mix method survey determin exercis program prefer covid survey conduct identifi barrier facilit engag virtual person cancer specif exercis covid theori inform multi method cross section survey electron distribut individu cancer investig prefer toward exercis program covid respond previous particip exercis program compris two group experi virtual exercis program virtual taken part person exercis person quantit data summar descript qualit data themat categor use framework analysi find map implement model survey complet respons rate n respond identifi barrier attend person exercis program covid concern increas risk viral exposur virtual respond n report feel confid engag virtual exercis enhanc motiv access effect facilit virtual exercis person respond n identifi technolog barrier virtual exercis low motiv access exercis effect barrier toward virtual exercis sixti six percent n person respond report technolog support would increas willing exercis virtual appropri target support perceiv barrier access virtual exercis includ motiv access effect may becom facilit avail technolog support may increas engag individu cancer toward virtual exercis program
|
D000086382;D009369
|
T047;T191;T067
|
36,290,805
|
impact diabet short term long term outcom ampullari adenocarcinoma patient curat pancreatoduodenectomi mani studi confirm diabet associ prognosi mani malign cancer type howev impact diabet ampullari carcinoma ac investig
|
D014670;D003138;D000230;D003920
|
T023;T191;T047
|
36,289,569
|
influenc electron densiti acyl protect group select galactos format stereoselect format cis glycosid bond major bottleneck synthesi carbohydr investig electron densiti acyl protect group influenc stereoselect fine tune effici remot particip electron rich c pivaloyl galactos build block show unpreced select trifluoroacetyl counterpart electron withdraw group hand exhibit lower select cryogen infrar spectroscopi helium nanodroplet densiti function theori calcul reveal exist dioxolenium type intermedi reaction suggest remot particip pivaloyl protect group origin high select pivaloyl build block accord find select galactos build block glycosynthesi develop base ration consider subsequ employ autom glycan assembl exhibit complet stereoselect base obtain select glycosyl reaction result infrar spectroscopi densiti function theori suggest mechan reaction could proceed
|
D005690;D004583
|
T081;T123;T196;T109
|
36,289,564
|
real time fluoresc screen platform meat fresh meat fresh close relat food safeti human health receiv increas attent nowaday site visual screen meat fresh fast non destruct manner ration construct seri fluoresc probe jdcn jdns jdpi distinct electron withdraw substitut group base julolidin fuse coumarin probe underw aza michael addit follow elimin reaction cadaverin generat colorimetr ratiometr fluoresc respons sens perform ration enhanc improv electron withdraw strength substitut group particular jdcn dicyanovinyl group reaction site exhibit outstand sens perform includ rapid respons high select low detect limit nm furthermor jdcn fabric test kit detect cadaverin vapor high contrast fluoresc chang red green base two color visual cadaverin vapor site non contact non destruct monitor meat fresh success achiev good sens perform render jdcn test kit promis real time fluoresc screen platform rapid non destruct accur evalu meat fresh
|
D008460;D003124
|
T168;T059
|
36,289,562
|
transcriptom differ monozygot adolesc twin discord metabol syndrom follow weight loss case studi case report peripher blood mononuclear cell pbmc transcriptom chang pair male monozygot pediatr twin metabol syndrom met undertak assist weight loss year old boy present similar baselin biochemistri bodi composit week weight loss intervent percent bodi weight loss similar twin twin b met resolv twin twin b maintain elev triglycerid weight loss analysi pbmc transcriptom weight loss reveal differ chang gene express includ differ direct express gene relat immun cell activ gene downregul twin upregul twin b case highlight novel approach report influenc chronic low grade inflamm metabol dysfunct pbmc transcriptom explor whether express gene relat immun function may underli differ respons weight loss whether transcriptom alter immun cell may preced tradit biomark chronic pro inflamm monozygot twin present exampl diverg phenotyp outcom despit ident genet background similar treatment respons
|
D059467;D024821
|
T081;T047;T086
|
36,289,554
|
tocilizumab relaps remit giant cell arter case seri giant cell arter larg vessel vascul arteri head neck mainstay manag high dose corticosteroid patient often face difficulti stop reduc steroid without recurr symptom corticosteroid well establish numer associ side effect includ osteoporosi weight gain diabet therefor tocilizumab approv year case relaps refractori giant cell arter nation institut health care excel nice april offer opportun benefit new fund reduc steroid burden
|
D013700
|
T047
|
36,289,548
|
engin global transcript factor frur redirect carbon flow escherichia coli enhanc l phenylalanin biosynthesi catabolit repressoractiv protein frur global regulatori protein known control express sever gene concern carbon util energi metabol studi aim illustr effect frur mutant l phenylalanin l phe produc strain phe
|
D004926;D029968
|
T007;T116
|
36,289,547
|
hybrid approach long stand persist atrial fibril immedi versus stage treatment hybrid approach becom effect treatment option restor sinus rhythm reduc risk atrial fibril af recurr howev sever issu remain clear defin includ appropri time stage procedur effect strategi
|
D001281;D017115;D011667
|
T061;T047;T046;T023
|
36,289,546
|
non clinic safeti evalu salvianol acid acut week intraven toxic genotox evalu toxicolog problem associ herbal medicin signific public health problem henc necessari elabor safeti herbal medicin salvianol acid saa major activ compound isol danshen popular herbal drug medicin food plant china aim present studi explor toxicolog profil saa
|
D002109;D007773
|
T123;T109
|
36,289,544
|
lamc mark tumor initi cell popul aggress signatur pancreat cancer tumor initi cell tic also known cancer stem cell consid specif subpopul cell necessari cancer initi metastasi howev mechan acquir metastat trait well understood
|
D021441;D010190
|
T191
|
36,289,543
|
knowledg covid impact indig access healthcar burkina faso covid constitut global health emerg unpreced proport prevent measur howev run certain difficulti low middl incom countri case social geograph margin communiti exclud inform prevent measur studi contain dual object assess knowledg covid prevent measur associ concern indig villag diebougou district burkina faso aim understand determin understand exist ii describ pathway healthcar chang covid pandem
|
D000086382
|
T047;T067
|
36,289,542
|
frequenc proport pf ild prognost factor patient acut exacerb ild relat system autoimmun diseas acut exacerb ae system autoimmun diseas relat interstiti lung diseas said ild less common ae idiopath pulmonari fibrosi ipf detail ae said ild elucid prognosi similar devast studi undertaken determin incid ae ild said elucid proport progress fibros pf ild ae said ild
|
D017563;D054990;D012595;D001327
|
T047
|
36,289,541
|
interdisciplinari collabor across secondari primari care improv medic safeti elder immens studi random control trial suboptim medic use contribut substanti proport hospit emerg depart visit older adult design clinic pharmacist intervent optim medic therapi older hospit patient base integr medicin manag imm model step immens intervent compris medic reconcili medic review reconcil medic list upon discharg patient counsel post discharg communic primari care object studi evalu effect intervent healthcar use mortal
|
D010351;D000359
|
T058
|
36,289,540
|
transcript regul mechan wheat varieti differ nitrogen use effici respons nitrogen defici stress one microel nitrogen play essenti role cereal product although use chemic fertil signific improv yield wheat also caus increas advers environment pollut reveal molecular mechan manipul wheat nitrogen use effici nue cultiv wheat germplasm high nitrogen use effici becom import goal wheat research studi investig physiolog transcript differ three wheat cultivar differ nue low nitrogen stress
|
D009584;D014908
|
T123;T196;T168;T002
|
36,289,538
|
screen brief intervent alcohol use disord risk three middl incom countri studi examin preval screen brief intervent sbi alcohol use disord aud risk sampl adult drinker three middl incom countri brazil china south africa extent meet criteria aud risk associ sbi
|
D000437
|
T048
|
36,289,537
|
technic feasibl use auditori phase target stimul pediatr sever traumat brain injuri intens care set supplementari treatment option pediatr sever traumat brain injuri tbi need improv neurodevelopment outcom evid suggest enhanc brain delta wave via auditori phase target stimul might support neuron reorgan howev method never appli analgosed patient pediatr intens care unit picu therefor conduct feasibl studi investig approach first record phase examin feasibl record time second stimul phase appli stimul address toler efficaci
|
D000070642
|
T037
|
36,289,536
|
associ triglycerid glucos index nonalcohol fatti liver diseas type diabet mellitus lipid glucos metabol abnorm associ nonalcohol fatti liver diseas nafld triglycerid glucos tyg index recent develop indic identifi individu risk nafld howev applic tyg index identifi nafld patient type diabet mellitus tdm unclear aim studi investig abil tyg index identifi individu risk nafld tdm popul
|
D065626;D003924
|
T047
|
36,289,534
|
method teach evid base practic systemat review identifi effect differ teach modal student evid base practic ebp compet
|
D055317;D006281
|
T169;T091
|
36,289,533
|
dusp phlda mutat matur cystic teratoma ovari identifi whole exom sequenc may explain teratoma characterist matur cystic teratoma ovari common type germ cell tumor compris ovarian tumor studi tumor may result better understand stepwis development process molecular base provid use inform develop tissu engin technolog
|
D013724;D010051
|
T191
|
36,289,532
|
efficaci safeti cpx versus chemotherapi european leukemianet risk subgroup older adult newli diagnos high risksecondari aml post hoc analysi random phase trial cpx europ vyxeo liposom unit state vyxeo dual drug liposom encapsul daunorubicin cytarabin synergist molar ratio phase studi older adult newli diagnos high risksecondari aml cpx improv remiss frequenc overal surviv post transplant surviv versus post hoc analysi evalu final year follow outcom accord european leukemianet risk classif cpx treat patient higher remiss frequenc advers risk vs intermedi risk vs longer median overal surviv advers risk vs month intermedi risk vs month post transplant surviv advers risk vs month intermedi risk reach vs month versus outcom general poorer among patient advers risk aml safeti profil cpx among patient advers risk intermedi risk aml consist overal studi popul earli mortal lower hospit length stay per patient year shorter cpx versus within advers risk intermedi risk subgroup favor outcom observ cpx post hoc analysi consist result overal studi popul support use cpx patientsclinicaltrialsgov identifi nct
|
D015470;D016609
|
T191
|
36,289,531
|
impact covid pandem harm reduct servic catalonia experi peopl use drug harm reduct profession harm reduct servic profession reorganis adapt covid prevent measur still ensur health social servic peopl use drug pud
|
D040261;D000086382
|
T061;T047;T067
|
36,289,530
|
influenc mechan use behavior clinic practic guidelin antimicrobi evid integr theori reason action organiz readi chang confront serious challeng antimicrobi resist use clinic practic guidelin cpgs standard prescript behavior vital howev overal mechan remain larg unknown guidelin use behavior improv studi aim identifi determin investig relationship bridg knowledg gap overal influenc mechan use behavior cpgs antimicrobi
|
D010820;D000890
|
T121;T097
|
36,289,529
|
type diabet remiss roux en gastric bypass rygb sleev gastrectomi sg one anastomosi gastric bypass oagb result longitudin assess bariatr surgeri studi sever studi various bariatr surgeri involv patient type diabet mellitus tdm show overal rate remiss hyperglycemia howev littl known predict factor remiss differ type surgeri aim studi identifi tdm remiss rate determin effect preoper factor characterist remiss type diabet iran
|
D015390;D003924;D009767;D050110;D061385
|
T061;T121;T047
|
36,289,527
|
clinic impact lipid inject emuls intern medicin inpati exclus receiv parenter nutrit propens score match analysi japanes medic claim databas although guidelin recommend lipid inject emuls ile use part parenter nutrit mani patient japan receiv lipid free parenter nutrit furthermor littl known effect ile clinic outcom medic inpati manag parenter nutrit aim studi investig clinic impact ile intern medicin inpati receiv parenter nutrit
|
D005217;D007297
|
T121;T101;T109
|
36,289,526
|
respect matern care health center addi ababa citi mix method studi studi aim assess qualiti obstetr newborn care includ respect matern care
|
D008427
|
T058
|
36,289,525
|
concanavalin promis lectin base anti cancer agent molecular mechan therapeut potenti concanavalin cona studi plant lectin known potent anti neoplast agent long time sinc initi report capac kill cancer cell much attent devot unveil lectin exact molecular mechan reveal cona bind sever receptor cancer normal cell modul relat signal cascad studi host receptor cona mt mmp respons lectin modul rang activ immun cell kill tumor cell studi addit studi effect cona signal immun cell function focus date advanc unravel molecular mechan cona induc autophagi apoptosi various cancer cell type found p jakstat lead player moreov discuss main signal molecul caus liver injuri signific side effect lectin inject altogeth find may shed light complex signal pathway control divers respons creat via cona treatment therebi modul complex network creat potent lectin base cancer therapi video abstract
|
D037102;D009369
|
T123;T191;T116
|
36,289,524
|
respons driven learn primari care qualit evalu medic student covid volunt programm first wave pandem clinic placement suspend uk medic student volunt programm develop support local gp practic studi aim explor impact volunt primari care student learn profession develop inform design futur servic learn curricula innov
|
D013337;D000086382
|
T047;T067;T097
|
36,289,519
|
gsk necrostatin protect retin ganglion cell necroptosi inhibit ripripmlkl pathway glutam induc retin excitotox model glaucoma glaucoma major caus irrevers blind worldwid character progress degener retin ganglion cell rgcs current treatment glaucoma slow partial prevent diseas progress fail prevent rgcs death visual field defect complet glutam excitotox via n methyl aspart acid nmda receptor play vital role rgcs death glaucoma often accompani oxid stress nlrp inflammasom activ howev exact mechan remain unclear
|
D000079302;D005901
|
T047;T043
|
36,289,518
|
screen prostat cancer protocol updat multipl systemat review inform canadian task forc prevent health care guidelin updat inform updat recommend canadian task forc prevent health care screen prostat cancer adult age year older primari care protocol outlin plan scope method seri systemat review
|
D017430;D011471
|
T129;T191;T126;T116
|
36,289,517
|
target err promot cytotox effect acut myeloid leukemia suppress mitochondri oxid phosphoryl acut myeloid leukemia aml aggress blood cancer poor clinic outcom emerg data suggest mitochondri oxid phosphoryl mtoxpho play signific role aml tumorigenesi progress resist chemotherapi howev mtoxpho regul aml cell well understood studi investig oncogen function err aml combin silico vitro vivo analys show err key regul mtoxpho aml cell increas err level associ wors clinic outcom aml patient singl cell rna seq analysi human primari aml cell indic err express cancer cell signific higher mtoxpho enrich score blockad err pharmacolog inhibitor xct gene silenc suppress mtoxpho increas anti leukem effect vitro xenograft mous model
|
D015470;D000970
|
T121;T191;T109
|
36,289,516
|
develop multicellular vitro model mening blood csf barrier studi neisseria meningitidi infect bacteri mening life threaten diseas occur pathogen neisseria meningitidi cross mening blood cerebrospin fluid barrier mbcsfb infect mening due human specif natur n meningitidi previous research investig complex host pathogen interact most done vitro use immort brain endotheli cell bec alon often retain relev barrier properti cultur develop physiolog relev mbcsfb model use bec co cultur leptomening cell lmcs examin n meningitidi interact
|
D009345;D008577
|
T007;T191
|
36,289,514
|
echinococcus granulosus sensu stricto antigen b may decreas inflammatori bowel diseas regul polar inflammatori bowel diseas ibd chronic idiopath diseas character inflamm relat epitheli barrier damag intestin tract helminth infect reduc autoimmun diseas symptom regul inflammatori respons base hygien theori howev under mechan remain unclear
|
D003092;D048209;D015212
|
T047;T204
|
36,289,513
|
fluorid exposur blood cell marker inflamm children adolesc unit state nhane ingest fluorid drink water shown result increas cellular marker inflamm rodent model howev approxim increas water fluorid concentr requir rat mous model obtain plasma fluorid concentr similar found human made relev comparison anim human studi difficult assess increas white blood cell count wbc marker inflamm human use avail nhane survey data assess associ plasma fluorid level us blood cell count children adolesc method multipl linear regress done determin associ blood cell count plasma fluorid public avail nhane survey data cycl plasma fluorid concentr measur avail children age inclus therefor subpopul use analys covari predictor along plasma fluorid age ethnic gender bodi mass index bmi result plasma fluorid signific posit associ water fluorid total wbc count segment neutrophil monocyt negat associ red blood cell count adjust age gender bmi
|
D005459;D060766
|
T121;T197;T167
|
36,289,512
|
earli corticosteroid dose taper patient acut exacerb idiopath pulmonari fibrosi although corticosteroid therapi dose taper common use treatment acut exacerb idiopath pulmonari fibrosi ae ipf consensus taper regimen studi aim investig associ earli corticosteroid dose taper hospit mortal patient ae ipf
|
D054990;D054988
|
T047
|
36,289,511
|
nurs experi increas clinic organis compet work medic qualiti regist revnatus qualit studi revnatus consent base nationwid medic qualiti regist collect data patient inflammatori rheumat diseas pregnanc one year postpartum enter data take place outpati clinic rheumatolog ward hospit aim studi explor rheumatolog nurs experi organ work medic qualiti regist revnatus addit normal clinic patient care task
|
D002983;D012216
|
T047;T080
|
36,289,510
|
perfluorin compound adult associ fast glucos incid diabet prospect cohort studi endocrin disrupt perfluorin compound emerg issu aim examin associ serum perfluorooctano acid pfoa perfluorooctanesulfon acid pfos level incid diabet fast serum glucos concentr
|
D005466;D017738;D003920
|
T047;T109
|
36,289,509
|
mechan action zishen yutai pill treat prematur ovarian failur determin integr uhplc q tof ms network pharmacolog analysi zishen yutai zsyt pill patent chines medicin wide use treatment infertil abort adjunct treatment vitro fertil ivf decad recent result clinic observ show prematur ovarian failur pof patient exhibit improv express steroid clinic symptom associ hormon disord treatment zishen yutai pill howev pharmacolog mechan action pill remain unclear
|
D016649
|
T047
|
36,289,508
|
measur hear impair among greenland school children associ self report data clinic examin multipl ear infect caus hear impair among children world health social consequ track earli adolesc later life treat monitor preval popul import assess need intervent popul
|
D034381;D006310
|
T033;T047;T074
|
36,289,507
|
pathogenesi coronavirus diseas sever acut respiratori syndrom associ coronavirus sar cov causal agent coronavirus diseas covid system ill character variabl sever pulmonari symptom cardiac conduct abnorm diarrhea gastrointestin bleed well neurolog deficit renal insuffici myalgia endocrin abnorm perturb reflect widespread microvascular injuri pro inflammatori state mechan under various manifest viral infect incomplet understood data suggest sever covid result virus driven perturb immun system result tissu injuri aberr interferon relat respons lead alter cytokin elabor deplet resid immun cell simultan recruit hyperact macrophag function alter neutrophil therebi tip balanc adapt immun innat immun disproportion activ macrophag neutrophil deplet normal activ b cell cell natur killer nk cell addit pro inflammatori state stimul uncontrol complement activ develop neutrophil extracellular trap net promot coagul cascad induc state thrombo inflamm perturb similar manifest multipl organ system frequent show patholog find relat microvascular injuri thrombosi larg small vessel howev pulmonari find patient sever covid general pronounc organ featur inflammatori thrombos endotheli injuri much parenchym damag stem fail matur alveolar pneumocyt interact type pneumocyt non resid macrophag greater degre net format purpos review discuss pathogenesi under organ damag occur patient sar cov infect understand mechan injuri import develop futur therapi patient covid mani like target specif compon immun system particular net induct pro inflammatori cytokin subpopul immun cell
|
D000086382;D013927
|
T047;T046;T067
|
36,289,506
|
emoji readi promot moment hand hygien healthcar hand hygien univers recogn cornerston measur prevent healthcar associ infect although five moment hand hygien poster use decad delin hand hygien indic promot action adher level among healthcar worker still notori low disquiet compens lack effect hand hygien communic aim evalu emoji possibl surrog non verbal aspect hand hygien behaviour
|
D063373;D003428
|
T055;T047
|
36,289,505
|
patient variabl blood stage dynam plasmodium falciparum captur cluster histor data mathemat model provid understand dynam plasmodium falciparum blood stage infect within host model predict impact control strategi affect blood stage malaria howev dynam p falciparum blood stage infect high variabl individu within host model use differ techniqu captur inter individu variat struggl may unnecessari patient cluster accord similar key within host dynam studi aim identifi cluster patient similar parasitaemia profil futur mathemat model includ improv understand within host variat
|
D016778;D008288
|
T047
|
36,289,504
|
analysi enhanc risk manag ethnic differ antineoplast drug japan risk manag post market phase crucial minim health problem caus drug ethnic factor may affect drug safeti object studi explor concret approach reflect ethnic factor risk manag multi region drug develop
|
D064420;D000970
|
T121;T046;T037;T109
|
36,289,503
|
marijuana use dna methyl base biolog age young adult marijuana third common use drug usa effort legal medic recreat use grow despit increas use marijuana effect age remain understudi understand effect marijuana molecular age may provid novel insight role marijuana age process therefor sought investig associ cumul recent use marijuana epigenet age acceler eaa estim blood dna methyl
|
D019175;D000074609
|
T055;T044;T048
|
36,289,501
|
impact school base malaria intervent primari school teacher time malawi evid time motion studi school base health sbh programm conting primari school teacher option increas access malaria treatment among learner howev percept provis healthcar teacher may detriment teach activ undermin effort scale school base malaria control object studi assess impact school base malaria diagnosi treatment use learner treatment kit ltk teacher time
|
D000070777;D008288
|
T047;T097
|
36,289,500
|
novel surgic techniqu transforamin lumbar interbodi fusion bone graft deliveri devic evalu therapeut effect patient minim invas spine surgeri transforamin lumbar interbodi fusion tlif common associ higher complic longer oper time studi aim evalu effect safeti usabl novel minim invas surgeri mis bone graft deliveri devic
|
D013123;D013168
|
T061;T047
|
36,289,499
|
spinal microglia contribut sustain inflammatori pain via amplifi neuron activ microglia high dynam immun cell central nervous system cns microgli process interact neuron element constant order minut function signific acut microglia neuron interact potenti role context pain still larg unknown found spinal microglia increas process motil electrophysiolog reactiv within hour insult mous model formalin induc acut sustain inflammatori pain use ablat strategi specif deplet resid microglia cns demonstr microglia particip formalin induc acut sustain pain behavior amplifi neuron activ spinal dorsal horn moreov identifi py receptor specif express microglia cns requir microgli function formalin induc pain taken togeth studi provid novel insight contribut microglia py receptor inflammatori pain could use potenti therapeut strategi
|
D017628;D009437
|
T184;T047;T025
|
36,289,498
|
communiti network sport physic activ promot analysi structur properti condit cooper import intersector cooper network among communiti organ locat peopl immedi environ address popul health problem physic inact come focus recent year date limit evid network emerg therefor aim studi analyz structur properti b identifi condit cooper interorganiz communiti network sport physic activ promot
|
D019058;D013177
|
T054;T056;T093
|
36,289,496
|
clinician choos conflict discord systemat review replic studi jadad algorithm exponenti growth publish systemat review srs present challeng decis maker seek answer clinic public health polici question algorithm creat jadad et al choos best sr across multipl studi aim replic author assess use jadad algorithm determin chose sr author ii reach result
|
D000465;D012108
|
T170;T097
|
36,289,495
|
conserv therapi associ wors clinic featur biochem derang renal replac therapi retrospect studi kumasi ghana incid end stage kidney diseas eskd increas ghana rest world studi compar sociodemograph diagnost characterist clinic biochem imag clinic outcom eskd patient chose either renal replac therapi rrt conserv therapi well factor influenc choic
|
D007676;D008687
|
T121;T047;T109
|
36,289,494
|
singl cell rna sequenc reveal landscap target treatment ferroptosi retin ischemiareperfus injuri aim studi establish complet retin cell atlas ischemia reperfus injuri singl cell rna sequenc explor under mechan retin ischemia reperfus injuri mice
|
D000079403;D015427
|
T037;T043
|
36,289,493
|
perin stress predictor perform episiotomi primipar women prospect observ studi episiotomi surgic solut reliev perin stress result easili repair incis comparison risk serious vagin trauma deliveri midwif typic adopt clinic decis experi subject judgment howev associ perin stress episiotomi poor character aim identifi threshold valu perin stress lead episiotomi eventu may employ clinic tool assess whether episiotomi requir
|
D007744
|
T046
|
36,289,491
|
enrich oper room base student learn experi explor factor develop curricular guidelin oper room high pressur set multipl complex surgic educ administr facet interplay contrari resid train dynam undergradu medic student learn process high demand opportunist unstandard suboptim owe mani reason upon review exist publish literatur regard medic student experi set clear field still date unstructur ambigu mani grey area need work achiev optim enhanc theatr experi immens import recogn recurr theme affect medic student within set deduc way overcom challeng studi explor priorit factor influenc base student learn qualiti develop guidelin structur clinic encount within set
|
D013337;D004501
|
T065;T097
|
36,289,489
|
combin therapi budesonid n acetylcystein amelior lps induc ali attenu neutrophil recruit mir b psoc molecular axi neutrophil infiltr acceler inflammatori respons high correl develop acut lung injuri ali budesonid bud n acetylcystein nac inhibit inflammatori respons allevi ali investig whether combin better ali
|
D055371;D035683
|
T123;T037;T114
|
36,289,488
|
oncolog obstetr result radic trachelectomi fertil spare therapi earli stage cervic cancer patient studi explor oncolog obstetr result radic trachelectomi rt earli stage cervic cancer patient
|
D000069339;D002583
|
T061;T191
|
36,289,487
|
covid vaccin coverag among patient psychiatr disord china pandem cross section studi investig coronavirus diseas covid vaccin coverag influenti factor vaccin among patient mental disord conduct cross section studi china
|
D000086382;D014612;D001523
|
T129;T121;T116;T067;T047;T048
|
36,289,485
|
tuberculosi treatment adher era covid person direct observ therapi dot common use tuberculosi tb treatment monitor us increas usag video dot vdot evalu impact covid tb treatment adher util effect vdot
|
D000086382;D017216;D014376
|
T047;T058;T067
|
36,289,484
|
screen evalu cytotox antivir effect secondari metabolit water extract bersama abyssinica sar cov delta bersama abyssinica common herb africa divers medic use differ area plant well known tanzania treat respiratori disord tb tonsil bronchiti asthma late util treat covid symptom water extract leaf stem bark regist herbal medic known coviba dawa tanzania relief bacteri respiratori infect extract howev scientif test anti viral activ aim work test cytotox antivir effect bioactiv ingredi b abyssinica extract delta variant sar cov coronavirus
|
D000086382;D019684
|
T047;T002;T067
|
36,289,483
|
educ physician strong opioid descript versus simul experi format random control trial long term prescript strong opioid chronic noncanc pain support scientif evid suggest miscalibr risk percept among prescrib dispens take opioid risk percept behavior differ depend whether peopl learn risk descript experi investig effect descript versus simul experi educ format physician risk percept strong opioid prescript behavior manag chronic noncanc pain
|
D059350;D010820
|
T184;T047;T097
|
36,289,482
|
similar differ sunct suna cross section multicentr studi patient china short last unilater neuralgiform headach attack conjunctiv inject tear sunct short last unilater neuralgiform headach attack cranial autonom symptom suna evalu suffici due limit data particular china
|
D050798;D009437
|
T184;T047
|
36,289,481
|
transport depend uptak metabol myocardi interstiti serotonin rat heart investig role serotonin ht transport sert plasma membran monoamin transport pmat ht uptak metabol heart monitor myocardi interstiti level ht hiaa metabolit ht monoamin oxidas mao anesthet rat use microdialysi techniqu fluoxetin sert inhibitor decynium pmat inhibitor mixtur local administ revers microdialysi min subsequ pargylin mao inhibitor co administ fluoxetin rapid increas dialys ht concentr decynium gradual increas mixtur induc larger increas dialys ht concentr compar fluoxetin decynium alon fluoxetin increas dialys hiaa concentr increas abolish pargylin decynium mixtur chang dialys hiaa concentr affect pargylin sert pmat regul myocardi interstiti ht level uptak howev ht uptak via pmat lead ht metabol mao
|
D008996;D012701
|
T121;T123;T109
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.